Advertisement

Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma

Published:October 23, 2015DOI:https://doi.org/10.1016/j.trsl.2015.10.002
      There is an increasing interest in using long noncoding RNAs (lncRNAs) as biomarkers in cancer. Predictive biomarkers in hepatocellular carcinoma (HCC) have great benefit in the choice of therapeutic modality for HCC. The aim of this study is to assess lncRNA–urothelial carcinoma associated-1 (lncRNA-UCA1) and WD repeat containing, antisense to TP53 (WRAP53) expression as novel noninvasive biomarkers for diagnosis of HCC in sera of HCC patients compared with chronic hepatitis C virus (HCV) patients and healthy volunteers and to analyze their relationship with respect to the clinicopathologic features. We retrieved HCC characteristic lncRNAs, lncRNA-UCA1 and lncRNA-WRAP53, based on the microarray signature profiling (released by LncRNADisease database). Quantitative reverse-transcriptase polymerase chain reaction assay (RT-qPCR) was then used to evaluate the expression of selected lncRNAs in the serum of 160 participants. Furthermore, in 20 of 82 HCC cases involved in the study, we examined the expression of lncRNA-UCA1 and lncRNA-WRAP53 in 20 HCC tissues and adjacent nontumor tissues and analyzed its correlation with the serum level of these lncRNAs. The prognostic significance of the investigated parameters in HCC patients was explored. We found that lncRNA-UCA1 and lncRNA-WRAP53 were significantly higher in sera of HCC than those with chronic HCV infection or healthy volunteers. Our data suggested that the increased expression of UCA1 and WRAP53 was associated with advanced clinical parameters in HCC. Of note, tissue levels of the chosen lncRNAs strongly correlate with their sera level. The combination of both lncRNAs with serum alpha fetoprotein resulted in improved sensitivity to 100%. The median follow-up period was 21.5 months. LncRNA-WRAP53 was significant independent prognostic markers in relapse-free survival. LncRNA-UCA1 and lncRNA-WRAP53 upregulation may serve as novel serum biomarkers for HCC diagnosis and prognosis.

      Abbreviations:

      ALT (Alanine transaminase), AST (Aspartate transaminase), AFP (Alpha fetoprotein), CHC (Chronic HCV infection), HCC (Hepatocellular Carcinoma), lncRNA-UCA1 (Long noncoding RNA–Urothelial Carcinoma Associated-1), WRAP53 (WD repeat containing, antisense to TP53), qPCR (Quantitative reverse-transcriptase polymerase chain reaction assay)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Stewart BW & Wild CP In Liver cancer, World Cancer Report 2014 (IARC, 2014).

        • Park Y.N.
        Update on precursor and early lesions of hepatocellular carcinomas.
        Arch Pathol Lab Med. 2011; 135: 704-715
        • National Cancer Registry of Egypt
        Magnitude of hepatocellular carcinoma in Egypt.
        2010 (Available at: http://www.nci.cu.edu.eg [updated 2010 August 6])
        • El-Serag H.B.
        Epidemiology of hepatocellular carcinoma in USA.
        Hepatol Res. 2007; 37: S88-S94
        • Bruix J.
        • Sherman M.
        Management of hepatocellular carcinoma: an update.
        Hepatology. 2011; 53: 1020-1022
        • Esteller M.
        Non-coding RNAs in human disease.
        Nat Rev Genet. 2011; 12: 861-874
        • Ling H.
        • Fabbri M.
        • Calin G.A.
        MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
        Nat Rev Drug Discov. 2013; 12: 847-865
        • Huang J.L.
        • Zheng L.
        • Hu Y.W.
        • et al.
        Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma.
        Carcinogenesis. 2014; 35: 507-514
        • Prensner J.R.
        • Chinnaiyan A.M.
        The emergence of lncRNAs in cancer biology.
        Cancer Discov. 2011; 1: 391-407
        • Ishibashi M.
        • Kogo R.
        • Shibata K.
        • et al.
        Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma.
        Oncol Rep. 2013; 29: 946-950
        • Lai M.C.
        • Yang Z.
        • Zhou L.
        • et al.
        Long noncoding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.
        Med Oncol. 2012; 29: 1810-1816
        • Zhang L.
        • Yang F.
        • Yuan J.H.
        • et al.
        Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma.
        Carcinogenesis. 2013; 34: 577-586
        • Du Y.
        • Kong G.
        • You X.
        • et al.
        Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18.
        J Biol Chem. 2012; 287: 26302-26311
        • Llovet J.M.
        • Brú C.
        • Bruix J.
        Prognosis of hepatocellular carcinoma: the BCLC staging classification.
        Semin Liver Dis. 1999; 19: 329-338
        • Child C.G.
        • Turcotte J.G.
        Surgery and portal hypertension.
        Major Probl Clin Surg. 1964; 1: 1-85
        • Pugh R.N.
        • Murray-Lyon I.M.
        • Dawson J.L.
        • et al.
        Transection of the oesophagus for bleeding oesophageal varices.
        Br J Surg. 1973; 60: 646-649
        • Livak K.J.
        • Schmittgen T.D.
        Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta deltaC(T)) method.
        Methods. 2001; 25: 402-408
        • Chatterjee R.
        • Mitra A.
        An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer.
        Int Immunopharmacol. 2015; 24: 335-345
        • Gibb E.A.
        • Brown C.J.
        • Lam W.L.
        The functional role of long non-coding RNA in human carcinomas.
        Mol Cancer. 2011; 10: 38
        • Morris K.V.
        Long antisense non-coding RNA function to direct epigenetic complexes that regulate transcription in human cells.
        Epigenetics. 2009; 4: 296-301
        • Halaby M.J.
        • Yang D.Q.
        p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics.
        Gene. 2007; 395: 1-7
        • Hung T.
        • Wang Y.
        • Lin M.F.
        • et al.
        Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.
        Nat. Genet. 2011; 43: 621-629
        • Martínez-Ló pez N.
        • Varela-Rey M.
        • Fernández-Ramos D.
        • et al.
        Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis.
        Hepatology. 2010; 52: 1621-1631
        • Wang Y.
        • Chen W.
        • Yang C.
        • et al.
        Long non-coding RNA UCA1 (CUDR) promotes proliferation and tumorigenesis of bladder cancer.
        Int J Oncol. 2012; 41: 276-284
        • Huang J.
        • Zhou N.
        • Watabe K.
        • et al.
        Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1).
        Cell Death Dis. 2014; 5: e1008
        • Han Y.
        • Yang Y.N.
        • Yuan H.H.
        • et al.
        UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution.
        Pathology. 2014; 46: 396-401
        • Wang F.
        • Ying H.
        • He B.
        • et al.
        Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.
        Oncotarget. 2015; 6: 7899-7917
        • Rui-Guo W.
        • Yuan S.
        • Qing L.
        • et al.
        DNA damage-induced lncRNA-UCA1 promotes HeLa cell proliferation.
        Chinese J Biochem Mol Biol. 2015; 31: 505-513
        • Katayama S.
        • Tomaru Y.
        • Kasukawa T.
        • et al.
        Antisense transcription in the mammalian transcriptome.
        Science. 2005; 309: 1564-1566
        • Mahmoudi S.
        • Henriksson S.
        • Corcoran M.
        • et al.
        Wrap53, anaturalp53 antisense transcript required for p53 induction upon DNA damage.
        Mol Cell. 2009; 33: 462-471
        • Wright C.M.
        • Kirschner M.B.
        • Cheng Y.Y.
        • et al.
        Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM).
        PLoS One. 2013; 8: e70940